Literature DB >> 18664342

Appropriately selecting and concisely reporting the outcome measures of randomized controlled trials of traditional Chinese medicine.

Zhao-xiang Bian1, David Moher, You-ping Li, Tai-xiang Wu, Simon Dagenais, Chung-wah Cheng, Jing Li, Ting-qian Li.   

Abstract

Evaluating outcome is the primary means by which different medical modalities can be compared with regard to effectiveness. In traditional Chinese medicine (TCM), this focus has prompted practitioners to search for outcome measures that can objectively verify the effectiveness of TCM interventions, especially in the context of randomized controlled trials (RCTs). Commonly used indexes for outcome assessment in RCTs of TCM can be categorized into two types: TCM-specific outcomes such as tongue and pulse characteristics, and Western medicine (WM)-specific outcomes such as blood test and X-ray examination results. Some studies include both types of indicators. During the trial design, it is necessary to consider the rationales of selecting outcome assessments, the purpose and study approach, balance between objective and subjective indexes, standardization of outcome assessment, and standardized outcome indexes. We recommend to report the outcome assessment in RCTs of TCM in the following format: 1) identifying the primary and secondary outcomes based on the purpose and hypothesis of the trial; 2) defining the primary and secondary outcomes clearly; 3) presenting the rationale of selection; 4) presenting the method with aims to standardize the assessment process; 5) presenting the method to improve the reliability of assessment; and 6) stating the termination criteria in the trial.

Mesh:

Year:  2008        PMID: 18664342     DOI: 10.3736/jcim20080801

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  7 in total

Review 1.  Modified Yupingfeng formula for the treatment of stable chronic obstructive pulmonary disease: a systematic review of randomized controlled trials.

Authors:  Yunqing Zhong; Xiufeng Wang; Guanglan Xu; Bing Mao; Wei Zhou; Jie Min; Hongli Jiang; Xiang Diao; Juanjuan Fu
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

Review 2.  Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation and future development.

Authors:  Zhaoxiang Bian; Baoyan Liu; David Moher; Taixiang Wu; Youping Li; Hongcai Shang; Chungwah Cheng
Journal:  Front Med       Date:  2011-06-22       Impact factor: 4.592

Review 3.  Developing traditional chinese medicine in the era of evidence-based medicine: current evidences and challenges.

Authors:  Foon Yin Fung; Yeh Ching Linn
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-08       Impact factor: 2.629

4.  WHO Trial Registration Data Set (TRDS) extension for traditional Chinese medicine 2020: recommendations, explanation, and elaboration.

Authors:  Xuan Zhang; Liang Lan; Jacky C P Chan; Linda L D Zhong; Chung-Wah Cheng; Wai-Ching Lam; Ran Tian; Chen Zhao; Tai-Xiang Wu; Hong-Cai Shang; Ai-Ping Lyu; Zhao-Xiang Bian
Journal:  BMC Med Res Methodol       Date:  2020-07-17       Impact factor: 4.615

Review 5.  Chinese herbal medicine for postinfectious cough: a systematic review of randomized controlled trials.

Authors:  Wei Liu; Hong-Li Jiang; Bing Mao
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-20       Impact factor: 2.629

Review 6.  An evaluation of randomized controlled trials on nutraceuticals containing traditional Chinese medicines for diabetes management: a systematic review.

Authors:  Junnan Shi; Hao Hu; Joanna Harnett; Xiaoting Zheng; Zuanji Liang; Yi-Tao Wang; Carolina Oi Lam Ung
Journal:  Chin Med       Date:  2019-11-29       Impact factor: 5.455

7.  PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration.

Authors:  Xuan Zhang; Ran Tan; Wai Ching Lam; Chung Wah Cheng; Liang Yao; Xiao-Qin Wang; Si-Yao Li; Qi-Ying Aixinjueluo; Ke-Hu Yang; Hong-Cai Shang; Tai-Xiang Wu; Ai-Ping Lyu; Zhao-Xiang Bian
Journal:  Syst Rev       Date:  2020-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.